Zhao et al. demonstrated that sorafenib upregulates HIF-2α by switching the hypoxia response from HIF-1α to HIF-2α-dependent pathways, resulting in the activation of the TGF-α/EGFR pathway, which contributes to the resistance of HCC cells to sorafenib [98]. This evidence concerns the gene EGFR and hepatocellular carcinoma.